Molecular imaging and radionuclide therapy · 2026
Quantitative characterization of 18F-PSMA-1007 and [68Ga]Ga-PSMA-11 PET-CT Imaging in Suspected Prostate Cancer: A Single-centre Experience.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sanghera Bal, Lowe Gerry, Sanghera Sophie, Wong Wai Lup
Аннотация
OBJECTIVES: We record quantitative differences between 18F-prostate specific membrane antigen (18F-PSMA)-1007 and [68Ga]Ga-PSMA-11 positron emission tomography (PET) prostate scans at our centre to investigate if significant differences exist between suspected lesion and lesion/ background parameters studied. We also assess the potential impact of such differences on tracer interchangeability when supply is constrained.
METHODS: Sixty-one [68Ga]Ga-PSMA-11 and seventy-two 18F-PSMA-1007 patients were analysed in two cohorts, each comprising 200 lesions. Clinical reports were used to determine maximum standard uptake values (SUVmax) was recorded for suspected lesions (T). Similarly, normalisations of mean standardized uptake (SUVmean) and standardized uptake value-peak (SUVpeak) using lean body mass (SUVIbm) and body surface area (SUVbsa) were estimated. SUVmean of liver backgrounds (B) was recorded to estimate T/B ratios. Metabolic tumour volume and total lesion PSMA (TL-PSMA) were investigated as functional volume surrogates. The Mann-Whitney U test was used to identify significant differences between the [68Ga]Ga-PSMA-11 and 18F-PSMA-1007 distributions.
RESULTS: Significant differences were observed for lesion SUVmax (p=0.0004), SUVpeak (p=0.0017), SUVmean (p=0.0007), SUVIbm (p=0.0002), and SUVbsa (p=0.0005) in lesions with higher [68Ga]Ga-PSMA-11 SUV. Similarly, significant differences were observed in liver SUVmax (p<0.0001), SUVpeak (p<0.0001), and SUVmean (p<0.0001), with higher values for 18F-PSMA-1007. T/B (p<0.0001) and TL-PSMA (p=0.0063) also exhibited significantly higher [68Ga]Ga-PSMA-11 values.
CONCLUSION: Consistent, predictable, and significant differences were observed in 18F-PSMA-1007 and [68Ga]Ga-PSMA-11 PET scans of lesion, liver, volume surrogates, supporting tracer interchangeability for patients with suspected prostate cancer. Our results also support the recent commissioning of PSMA-based PET tracers in England.
METHODS: Sixty-one [68Ga]Ga-PSMA-11 and seventy-two 18F-PSMA-1007 patients were analysed in two cohorts, each comprising 200 lesions. Clinical reports were used to determine maximum standard uptake values (SUVmax) was recorded for suspected lesions (T). Similarly, normalisations of mean standardized uptake (SUVmean) and standardized uptake value-peak (SUVpeak) using lean body mass (SUVIbm) and body surface area (SUVbsa) were estimated. SUVmean of liver backgrounds (B) was recorded to estimate T/B ratios. Metabolic tumour volume and total lesion PSMA (TL-PSMA) were investigated as functional volume surrogates. The Mann-Whitney U test was used to identify significant differences between the [68Ga]Ga-PSMA-11 and 18F-PSMA-1007 distributions.
RESULTS: Significant differences were observed for lesion SUVmax (p=0.0004), SUVpeak (p=0.0017), SUVmean (p=0.0007), SUVIbm (p=0.0002), and SUVbsa (p=0.0005) in lesions with higher [68Ga]Ga-PSMA-11 SUV. Similarly, significant differences were observed in liver SUVmax (p<0.0001), SUVpeak (p<0.0001), and SUVmean (p<0.0001), with higher values for 18F-PSMA-1007. T/B (p<0.0001) and TL-PSMA (p=0.0063) also exhibited significantly higher [68Ga]Ga-PSMA-11 values.
CONCLUSION: Consistent, predictable, and significant differences were observed in 18F-PSMA-1007 and [68Ga]Ga-PSMA-11 PET scans of lesion, liver, volume surrogates, supporting tracer interchangeability for patients with suspected prostate cancer. Our results also support the recent commissioning of PSMA-based PET tracers in England.